Skip to content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Advanced sporadic renal epithelioid angiomyolipoma: case report of an extraordinary response to sirolimus linked to TSC2 mutation

Contributed equally
BMC Cancer201818:561

https://doi.org/10.1186/s12885-018-4467-6

Received: 24 July 2017

Accepted: 30 April 2018

Published: 15 May 2018

Abstract

Background

Renal epithelioid angiomyolipomas (EAML) are rare tumors with aggressive behavior. EAML can be sporadic or develop within the tuberous sclerosis complex syndrome, where mutations of TSC1 or TSC2 genes (critical negative regulators of mTOR Complex 1) result in an increased activation of mTOR pathway. Optimal EAML treatment, including mTOR inhibitors, remains undetermined.

Case presentation

Here we present the case of a young adult with a renal EAML that after radical nephrectomy developed metastases, first in liver and then in lumbar vertebrae. After complete surgical resection of these lesions, liver recurrence was detected, this time with incomplete surgical resection. After finding a new liver lesion, systemic treatment with sirolimus started. The patient exhibited a complete and durable response to this drug, being disease free at the time of publication, after 36 months of treatment. Targeted next generation sequencing (NGS) of MTOR, TSC1 and TSC2 genes in the primary tumor, metastasis and blood of the patient, revealed one inactivating TSC2 mutation (c.2739dup; p.K914*) in the tumor cells. Immunohistochemistry revealed decreased TSC2 protein content and increased phospho-S6 in the tumor cells, demonstrating mTOR pathway activation.

Conclusion

NGS on an EAML patient with an extraordinary response to sirolimus uncovered TSC2 inactivation as the mechanism for the response. This study supports NGS as a useful tool to identify patients sensitive to mTOR inhibitors and supports the treatment of malignant EAML with these drugs.

Keywords

Renal epithelioid angiomyolipomaSirolimusTSC2 mutationmTOR pathway activation

Background

Angiomyolipomas (AML) are rare kidney tumors that occur in 0.2–0.3% of the population [1, 2]. These neoplasms are mesenchymal in origin and comprise blood vessels, mature adipose tissue and fusiform cells similar to smooth muscle. Depending on the major component, AML is histologically classified into fat-predominant, smooth muscle-predominant, epithelioid, oncocytic and sclerosant subtype [3]. Most AMLs are considered benign and have a primarily local growth. However, one particular subtype characterized by the presence of an epithelioid cellular morphology, named epithelioid AML (EAML), and included in the family of perivascular epithelioid cell tumors (PEComas) can have malignant behaviour [4, 5]. Histologically, EAML cells contain granular cytoplasm in more than 5% of tumor volume, with round nucleus and occasional multinucleated giant cells dispersed. They can co-express melanocytic and muscle markers and are negative for epithelial markers. The low percentage of fat is characteristic of this variety of AML and makes diagnosis difficult with CT or MRI.

The behaviour of EAML is variable, ranging from indolent, with only local growth, to aggressive, with potential for invasive growth and dissemination. This different behaviour seems to be determined by the presence or absence of cellular atypia and other clinical and pathological factors. The definition of atypical epithelioid cells in series of EAML includes atypical polygonal cells with abundant cytoplasm, vesicular nuclei, prominent nucleoli and nuclear size that exceeds twice the size of the adjacent nuclei. In a comparative analysis of the literature published by Brimo et al., 21 EAML cases with benign clinical course were compared with 9 EAML with malignant behaviour [6]. The aggressive cases tended to associate with older patients, larger tumor size, higher percentage of epithelioid component, severe atypia, higher percentage of atypical cells, higher mitotic count, atypical mitotic figures, necrosis, lymphovascular invasion, and renal vein invasion. A predictive model was developed that included the following factors: i) ≥ 2 mitotic figures per 10 high-power fields; ii) ≥ 70% atypical epithelioid cells; iii) atypical mitotic figures; iv) necrosis. The presence of 3 or more of these factors was highly predictive of malignant behaviour [6]. Moreover, the evaluation of another series of 41 EAML patients identified a number of clinico-pathologic parameters that also predicted for worse outcome including: i) tuberous sclerosis complex (TSC) or concurrent AML; ii) necrosis; iii) tumor size> 7 cm, iv) extra renal extension and/or vein involvement, v) carcinoma-like growth pattern. Based on these findings the authors suggested that EAML patients should be classified in groups with low, intermediate and high risk of disease progression, according to the presence of 0–1, 2–3 or 4–5 of these parameters, respectively [7].

Approximately 80% of AML are sporadic while 20% develop within the TSC [8]. AML tumors in the context of TSC present bi-allelic inactivating mutations in TSC1 or TSC2. These genes encode the proteins hamartin and tuberin responsible for the inhibition of the mammalian target of rapamycin (mTOR), a conserved protein kinase that regulates cell growth and metabolism in response to growth factors and nutrients [9]. Rapamycin and its analogs, sirolimus, everolimus and temsirolimus, inhibit mTOR pathway and are anti-tumor drugs used for metastatic renal cell carcinoma, pancreatic neuroendocrine tumors and advanced breast cancer. In addition, everolimus has shown significant efficacy to treat TSC neoplasms, including AML [10]. Significant clinical response to mTOR inhibitors has been described in patients with unresectable or recurrent PEComas, although specific data regarding EAML is scarce [11, 12]. Whenever possible, treatment of EAML should be surgery. Chemotherapy has limited benefit, while response to mTOR inhibitors, awaiting clinical trials, remains undetermined with only isolated cases reported in the literature with contradictory outcomes [1316].

In this study we performed a genomic and immunohistochemical characterization of an EAML patient that after developing hepatic and bone metastasis had a complete response to sirolimus, and 36 months after the start of treatment remains disease-free. The molecular mechanism responsible for this extraordinary response to sirolimus was identified by next generation sequencing (NGS) and immunohistochemistry (IHC).

Case presentation

We report the case of a Caucasian male patient aged 34 without an irrelevant past medical history that presented with unexplained weight loss. Imaging studies revealed the presence of a left renal mass of 10 × 12 cm (Fig. 1a-b). The patient underwent a left radical nephrectomy and the pathology was consistent with an EAML (Fig. 2a) with poor prognosis features (size > 7 cm, vascular and renal sinus invasion, necrosis, and severe atypia). Immunohistochemical profile revealed diffuse and intense expression of HMB-45 and Melan A (Fig. 2b-c), along with expression of smooth muscle actin and CD68 (KP-1, Ventana), and negativity for CD-31, CEA, CK-pan, desmin, EMA, Ki-67, myogenin and S-100. After nephrectomy the patient did not receive adjuvant therapy and started follow up in urology clinics. Seven months after primary surgery the patient developed 3 liver metastases (two in segment VIII of 6 cm and 1.5 cm, respectively, and one in segment IV of 2 cm). All these lesions were completely resected through a right partial hepatectomy with extension to segment IV through a split in situ technique. Again, adjuvant therapy was not administered. Five months later a new single metastasis developed in the first lumbar vertebrae, and was managed through a total L1 corpectomy. Six months after the spine surgery liver recurrence was observed, surgical resection was incomplete leaving positive margins and within 12 weeks a new liver lesion of 1.7 cm was detected. A new surgical attempt was considered not feasible and after reviewing the scarce existing literature, it was decided to start systemic treatment with sirolimus 6 mg/day [13]. After starting sirolimus treatment the patient presented a very unusual and favorable response (complete response after 13 months of treatment; Fig. 1c-d). Tolerance was excellent with grade 1 intermittent diarrhea and acne along with grade 1 hypophosphatemia. At the time of publication, after 36 months of treatment and about five years of the initial diagnosis, the patient remains free of disease and with an excellent performance status. Genetic testing was performed and ruled out TSC (no TSC1 or TSC2 germline mutations detected).
Figure 1
Fig. 1

Computed tomographic (CT) scans. Left renal mass of 10 × 12 cm at diagnosis (a and b). Liver recurrence (c) and response after 5 months of sirolimus treatment (d)

Figure 2
Fig. 2

Immunohistochemical study. Hematoxylin and eosin staining of the EAML primary tumor (a). Representative images for HMB-45 (b; × 10) and Melan A (c; × 10). TSC2 staining (Cell Signalling 4308) of the tumor metastasis, where tumor cells are negative for TSC2 while normal hepatocytes (indicated with an arrow and “N”) show high intensity. (d; 10×). Phospho-ribosomal protein S6 (S235/S236; Cell Signaling 2211) expression in the primary tumor (e; × 40) and liver metastasis (f; × 10)

Targeted NGS of MTOR, TSC1 and TSC2 genes was performed on DNA extracted from formalin-fixed paraffin-embedded primary tumor and hepatic metastasis, and the patient’s peripheral blood (TruSeq Custom Amplicon Low Input; Illumina). Primary tumor failed NGS due to poor DNA quality, however, the liver metastasis and the blood were successfully sequenced by NGS, with a mean coverage of 184× and 1643×, respectively, and single nucleotide variants and indels were identified. One TSC2 variant resulting in a premature stop codon (c.2739dup; p.K914*) was found in heterozygosity in the metastasis while it was absent in blood (Fig. 3a-b). Sanger sequencing validated this finding, and detected the TSC2 mutation also in the primary tumor (Fig. 3c). IHC revealed absence of TSC2 expression in the liver metastasis (Fig. 2d), in agreement with inactivation of TSC2. Phospho-ribosomal protein S6 staining was positive in the primary tumor and liver metastasis (Fig. 2e-f), indicating activation of the mTOR pathway in the patient’s tumors.
Figure 3
Fig. 3

Tumor TSC2 point mutation. Targeted NGS revealed one frameshift mutation in TSC2 gene (c.2739dup; p.K914*) absent in the patient’s blood (a) and present in the liver metastasis (b). The primary tumor DNA failed NGS technique, but Sanger sequencing detected the TSC2 mutation (c). Representative genome images from the Integrative Genomics Viewer (Broad Institute) are shown together with Sanger chromatograms

Discussion and conclusions

mTOR signaling pathway is up-regulated in many cancers and hamartoma syndromes through mutations in genes that participate in this pathway. Genetic events include activating mutations in MTOR and PIK3CA and inactivating mutations in TSC1, TSC2 and PTEN. Extraordinary responses to mTOR inhibitors are rare and have been described in patients with metastatic bladder cancer [17, 18], and in an anaplastic thyroid cancer patient [19]. In these cases, mutations in TSC1, TSC2 or MTOR were identified as the mechanism leading to the drug sensitivity. However, a recent study in renal cell carcinoma showed that some patients with mutations activating mTOR pathway did not respond to mTOR inhibitors, while some without mutations did [20], suggesting that tumor specific mechanisms may be modulating response. Thus, further investigation and cases with extraordinary responses are required to understand the mechanisms responsible for the sensitivity to mTOR inhibitors.

Genetic studies have shown that AML occur due to bi-allelic inactivation of either TSC2 or TSC1 [21]. In the case of TSC AML it is caused by a germline mutation in either of these genes plus a tumor second hit, while sporadic AML is almost exclusively caused by mutations in TSC2 [22, 23]. In both cases hyperactivation of mTORC1 occurs, leading to tumor development. In EAML, similarly to AML, TSC2 gene deletions seem to be frequent [24], however, studies are scarce. The EAML patient presented here is a sporadic case with a novel TSC2 mutation (c.2739dup, p.K914*), not described previously in COSMIC or in the germline TCS2 Leiden Open Variation Database (LOVD). However, the LOVD includes a sporadic TSC patient with a TSC2 protein truncated at Threonine 913 (c.2737_2738delAC), allowing to classify this novel variant as pathogenic. Inactivation of TSC2 and over-activation of mTORC1 in the tumor cells were confirmed by IHC, and were in agreement with the extraordinary response to sirolimus.

Previous studies have reported mTOR pathway activation for TSC1/TSC2 mutations in sporadic AML and PEComas [2527], suggesting that mTOR inhibition could potentially provide a therapeutic benefit. A double-blind, placebo-controlled, phase 3 trial tested the efficacy of the mTOR inhibitor everolimus in patients with AML associated with TSC or sporadic lymphangioleiomyomatosis. The study showed that everolimus was superior to placebo and reduced significantly AML volume with an acceptable safety profile, in 2012 this drug was approved for the treatment of adults with renal AML associated with TSC who do not require immediate surgery [28].

However, therapeutic experience with aggressive EAML is scarce. There are only about a dozen published cases in the literature in which EAML patients received mTOR inhibitors with variable outcomes. These reports consist on clinical descriptions that include favorable responses, in most of the cases with no genetic study associated [13, 14, 2931]. Additionally, other publications have reported unsatisfactory responses to mTOR inhibition [15, 16], suggesting differences in the driver pathways of these tumors.

In summary, only a few cases of EAML with benefit from mTOR inhibitors have been reported, and the mechanisms underlying these responses are unexplored. This study reveals TSC2 deficiency in a sporadic EAML patient as the mutation causative of an exceptional response to sirolimus. These results support NGS as a useful tool to predict sensitivity to mTOR inhibitors in patients with EAML, this rare and potentially aggressive urological malignancy is misrepresented in clinical trials.

Notes

Abbreviations

AML: 

Angiomyolipomas

EAML: 

Epithelioid angiomyolipomas

IHC: 

Immunohistochemistry

mTOR: 

Mammalian target of rapamycin

NGS: 

Next generation sequencing

PEComas: 

Perivascular epithelioid cell tumor

TSC: 

Tuberous sclerosis complex syndrome

Declarations

Acknowledgements

We thank Rocío Letón and Rafael Torres for their support in the generation of NGS libraries and analysis of the data.

Funding

This study was supported by projects SAF2015–70820-ERC and SAF2015–64850-R (Spanish Ministry of Economy, Industry and Competitiveness MEIC/AEI, co-funded by the European Regional Development Fund ERDF). Juan María Roldán-Romero and María Apellániz-Ruiz are predoctoral fellows of “la Caixa”/CNIO international PhD programme. The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials

The data generated and/or analyzed during this study are included in this published article.

Author’s contributions

ID and CR-A designed the research study; ME, JMR-R and MA-R conducted experiments; ME, ID and CG acquired the clinical data; EA performed immunohistochemistry; JMR-R, MA-R, AC, MR and CR-A performed analysis and interpretation of NGS data; ID and CR-A supervised the study; and all authors contributed to the writing, review, and revision of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was approved by the Hospital Institutional Review Board of the Hospital Universitario Virgen del Rocío (reference number 33140027), and the patient provided written informed consent to participate in the study.

Consent for publication

We obtained written informed consent of the patient for the publication of the case report and accompanying images.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Medical Oncology Department, Hospital Virgen del Rocío, Servicio de Oncología Medica, Sevilla, Spain
(2)
Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
(3)
Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain
(4)
Pathology Department, Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla-CIBERONC, Sevilla, Spain
(5)
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Valencia, Spain

References

  1. Fujii Y, Ajima J, Oka K, Tosaka A, Takehara Y. Benign renal tumors detected among healthy adults by abdominal ultrasonography. Eur Urol. 1995;27:124–7.View ArticlePubMedGoogle Scholar
  2. Fittschen A, et al. Prevalence of sporadic renal angiomyolipoma: a retrospective analysis of 61,389 in- and out-patients. Abdom Imaging. 2014;39:1009–13.View ArticlePubMedGoogle Scholar
  3. Lienert AR, Nicol D. Renal angiomyolipoma. BJU Int. 2012;110(Suppl 4):25–7.View ArticlePubMedGoogle Scholar
  4. He W, et al. Epithelioid angiomyolipoma of the kidney: pathological features and clinical outcome in a series of consecutively resected tumors. Mod Pathol. 2013;26:1355–64.View ArticlePubMedGoogle Scholar
  5. Faraji H, Nguyen BN, Mai KT. Renal epithelioid angiomyolipoma: a study of six cases and a meta-analytic study. Development of criteria for screening the entity with prognostic significance. Histopathology. 2009;55:525–34.View ArticlePubMedGoogle Scholar
  6. Brimo F, et al. Renal epithelioid angiomyolipoma with atypia: a series of 40 cases with emphasis on clinicopathologic prognostic indicators of malignancy. Am J Surg Pathol. 2010;34:715–22.PubMedGoogle Scholar
  7. Nese N, et al. Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: a clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification. Am J Surg Pathol. 2011;35:161–76.View ArticlePubMedGoogle Scholar
  8. Kwiatkowski DJ. Tuberous sclerosis: from tubers to mTOR. Ann Hum Genet. 2003;67:87–96.View ArticlePubMedGoogle Scholar
  9. Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;169:361–71.View ArticlePubMedGoogle Scholar
  10. Franz DN, et al. Long-term use of Everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study. PLoS One. 2016;11:e0158476.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Wagner AJ, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol. 2010;28:835–40.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Dickson MA, Schwartz GK, Antonescu CR, Kwiatkowski DJ, Malinowska IA. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates. Int J Cancer. 2013;132:1711–7.View ArticlePubMedGoogle Scholar
  13. Wolff N, et al. Sirolimus and temsirolimus for epithelioid angiomyolipoma. J Clin Oncol. 2010;28:e65–8.View ArticlePubMedGoogle Scholar
  14. Kohno J, et al. Role of mammalian target of rapamycin inhibitor in the treatment of metastatic epithelioid angiomyolipoma: a case report. Int J Urol. 2013;20:938–41.View ArticlePubMedGoogle Scholar
  15. Wyluda E, Baquero G, Lamparella N, Abendroth C, Drabick J. Fatal malignant metastastic epithelioid angiomyolipoma presenting in a young woman: case report and review of the literature. Rare Tumors. 2013;5:e46.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Higa F, et al. Malignant epithelioid angiomyolipoma in the kidney and liver of a patient with pulmonary lymphangioleiomyomatosis: lack of response to sirolimus. Intern Med. 2009;48:1821–5.View ArticlePubMedGoogle Scholar
  17. Iyer G, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338:221.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Wagle N, et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014;4:546–53.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Wagle N, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014;371:1426–33.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Kwiatkowski DJ, et al. Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2016;Google Scholar
  21. Henske EP, et al. Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas. Genes Chromosomes Cancer. 1995;13:295–8.View ArticlePubMedGoogle Scholar
  22. Qin W, et al. Angiomyolipoma have common mutations in TSC2 but no other common genetic events. PLoS One. 2011;6:e24919.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Giannikou K, et al. Whole exome sequencing identifies TSC1/TSC2 Biallelic loss as the primary and sufficient driver event for renal Angiomyolipoma development. PLoS Genet. 2016;12:e1006242.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Pan CC, et al. Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma. J Pathol. 2008;214:387–93.View ArticlePubMedGoogle Scholar
  25. Guo B, Song H, Yue J, Li G. Malignant renal epithelioid angiomyolipoma: a case report and review of the literature. Oncol Lett. 2016;11:95–8.View ArticlePubMedGoogle Scholar
  26. Citak EC, et al. Malignant epitheloid angiomyolipoma of the kidney in a child treated with sunitinib, everolimus and axitinib. Can Urol Assoc J. 2015;9:E542–5.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Kenerson H, Folpe AL, Takayama TK, Yeung RS. Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms. Hum Pathol. 2007;38:1361–71.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Bissler JJ, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381:817–24.View ArticlePubMedGoogle Scholar
  29. Nagashima Y. Editorial comment to role of mammalian target of rapamycin inhibitor in the treatment of metastatic epithelioid angiomyolipoma: a case report. Int J Urol. 2013;20:942.View ArticlePubMedGoogle Scholar
  30. Gennatas C, Michalaki V, Kairi PV, Kondi-Paphiti A, Voros D. Successful treatment with the mTOR inhibitor everolimus in a patient with perivascular epithelioid cell tumor. World J Surg Oncol. 2012;10:181.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Shitara K, et al. Dramatic tumor response to everolimus for malignant epithelioid angiomyolipoma. Jpn J Clin Oncol. 2011;41:814–6.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement